125 related articles for article (PubMed ID: 8583584)
21. Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer.
Elgamal AA; Cornillie FJ; Van Poppel HP; Van de Voorde WM; McCabe R; Baert LV
J Urol; 1996 Sep; 156(3):1042-7; discussion 1047-9. PubMed ID: 8709304
[TBL] [Abstract][Full Text] [Related]
22. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
[TBL] [Abstract][Full Text] [Related]
23. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
24. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy?
Soh S; Kattan MW; Berkman S; Wheeler TM; Scardino PT
J Urol; 1997 Jun; 157(6):2212-8. PubMed ID: 9146618
[TBL] [Abstract][Full Text] [Related]
25. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
26. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database.
Scales CD; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL; Freedland SJ;
J Urol; 2007 Oct; 178(4 Pt 1):1249-52. PubMed ID: 17698131
[TBL] [Abstract][Full Text] [Related]
27. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
28. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4.
Lau WK; Blute ML; Bostwick DG; Weaver AL; Sebo TJ; Zincke H
J Urol; 2001 Nov; 166(5):1692-7. PubMed ID: 11586204
[TBL] [Abstract][Full Text] [Related]
30. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
[TBL] [Abstract][Full Text] [Related]
31. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?
Loeb S; Yu X; Nadler RB; Roehl KA; Han M; Hawkins SA; Catalona WJ
J Urol; 2007 Jan; 177(1):102-6; discussion 106. PubMed ID: 17162013
[TBL] [Abstract][Full Text] [Related]
32. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
33. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L
BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921
[TBL] [Abstract][Full Text] [Related]
34. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy.
Kordan Y; Chang SS; Salem S; Cookson MS; Clark PE; Davis R; Herrell SD; Baumgartner R; Phillips S; Smith JA; Barocas DA
J Urol; 2009 Nov; 182(5):2291-5. PubMed ID: 19758638
[TBL] [Abstract][Full Text] [Related]
35. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
36. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
37. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
38. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
[TBL] [Abstract][Full Text] [Related]
39. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
[TBL] [Abstract][Full Text] [Related]
40. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H
J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
